MARKET

PTPI

PTPI

Petros Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8808
-0.0228
-2.52%
Opening 09:58 06/29 EDT
OPEN
0.9036
PREV CLOSE
0.9036
HIGH
0.9036
LOW
0.8410
VOLUME
84.48K
TURNOVER
52.70K
52 WEEK HIGH
5.20
52 WEEK LOW
0.6458
MARKET CAP
18.22M
P/E (TTM)
-0.7712
1D
5D
1M
3M
1Y
5Y
Petros Pharmaceuticals Said Received Letter from Listing Qualifications Department of the Nasdaq Stock Market that the Company Did Not Meet the Minimum Bid Price of $1.00/Share Required for Continued Listing
On June 22, 2022, Petros Pharmaceuticals, Inc.
Benzinga · 2d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Investor Place · 05/31 11:23
Petros Pharmaceuticals GAAP EPS of -$0.01, revenue of $2.47M
Petros Pharmaceuticals press release (NASDAQ:PTPI): Q1 GAAP EPS of -$0.01. Revenue of $2.47M (-39.5% Y/Y).
Seekingalpha · 05/16 21:25
BRIEF-Petros Pharmaceuticals Reports Q1 2022 Results
reuters.com · 05/16 21:10
-- Earnings Flash (PTPI) PETROS PHARMACEUTICALS Reports Q1 Revenue $2.5M
MT Newswires · 05/16 17:07
Petros Pharmaceuticals To Pursue 505(B)(2) Pathway For H-100, Company's Novel Topical Investigational Treatment For Peyronie's Disease Which Impacts More Than 1 In 10 Men In The Us
Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a leading provider of therapeutics for men's health, announces today they will be pursuing the 505(b)(2) pathway for its investigational agent, H-100™, a novel,
Benzinga · 05/03 13:24
Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company’s Novel Topical Investigational Treatment for Peyronie’s Disease Which Impacts More Than 1 in 10 Men in the US
Company Is Developing H-100 as Potentially the First FDA-Approved, Nanoparticle-Based Topical Treatment Designed to Provide Improved and Sustained Local Medication Permeation Against Peyronie’s Disease, Which is Currently Predominantly Treated Surgically, ...
GlobeNewswire · 05/03 13:23
28 Stocks Moving in Thursday's Pre-Market Session
Gainers T Stamp Inc. (NASDAQ: IDAI) shares rose 103.3% to $4.27 in pre-market trading after gaining over 8% on Wednesday. Trust Stamp recently posted Q4 net sales of $2.1 million.
Benzinga · 04/28 10:30
More
No Data
Learn about the latest financial forecast of PTPI. Analyze the recent business situations of Petros Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
No Data
About PTPI
Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on men's health therapeutics with a range of commercial capabilities including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. The Company is also focused on identifying, developing, acquiring, and commercializing therapeutics for men's health issues, including, erectile dysfunction (ED), endothelial dysfunction, psychosexual and psychosocial ailments, peyronie's disease, hormone health, and substance use disorders. The Company also markets its own line of ED products in the form of vacuum erection device (VED) products through its subsidiaries, Timm Medical, Inc. In addition, its ED products, the Company is focused on identifying and developing other pharmaceuticals to advance men's health, which is H100, which is the topical formulation candidate for the treatment of acute peyronie's disease.

Webull offers kinds of Petros Pharmaceuticals Inc stock information, including NASDAQ:PTPI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTPI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTPI stock methods without spending real money on the virtual paper trading platform.